Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.84 |
| ▸ | KDR | P35968 | 14/20 | 0.84 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.84 |
| ▸ | AXL | P30530 | 2/20 | 0.84 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.84 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | MERTK | Q12866 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tas-115 SCHEMBL1132590 | 0.91 | MET (1.00) | METKDRPDGFRAAXLPDGFRB | |
| Tas-115 SCHEMBL29853531 | 0.91 | MET (1.00) | METKDRPDGFRAAXLPDGFRB | |
| Tas-115 SCHEMBL16782348 | 0.89 | MET (0.94) | METKDRPDGFRAAXLPDGFRB | |
| SCHEMBL1132173 | 0.87 | MET (0.86) | METKDRPDGFRAAXLPDGFRB | |
| SCHEMBL1132323 | 0.85 | MET (0.78) | METKDRPDGFRAAXLPDGFRB | |
| SCHEMBL23677959 | 0.85 | MET (0.87) | METKDRPDGFRAAXLPDGFRB | |
| Hydrochloric Acid SCHEMBL1132688 | 0.84 | MET (0.77) | METKDRPDGFRAAXLPDGFRB | |
| SCHEMBL1132734 | 0.84 | MET (0.88) | METKDRPDGFRAAXLPDGFRB | |
| SCHEMBL1879278 | 0.84 | MET (0.87) | METKDRPDGFRAAXLPDGFRB | |
| SCHEMBL1132290 | 0.84 | MET (0.72) | METKDRPDGFRAAXLPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287155-B1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-8304427-B2 | Acylthiourea compound or salt thereof, and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-2287155-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR THE SALT | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034439-A1 | ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF | MET, HGF, STAT6 | MET 1/4885KDR 296/4885PDGFRA 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.